Literature DB >> 23374740

Nontraditional manifestations of primary hyperparathyroidism.

Marcella Donovan Walker1, Mishaela Rubin, Shonni J Silverberg.   

Abstract

Classical primary hyperparathyroidism (PHPT) was previously a multisystemic symptomatic disorder not only with overt skeletal and renal complications but also with neuropsychological, cardiovascular, gastrointestinal, and rheumatic effects. The presentation of PHPT has evolved, and today most patients are asymptomatic. Osteitis fibrosa cystica is rarely seen today, and nephrolithiasis is less common. Gastrointestinal and rheumatic symptoms are not part of the clinical spectrum of modern PHPT. It remains unclear whether neuropsychological symptoms and cardiovascular disease, neither of which are currently indications for recommending parathyroidectomy (PTX), are part of the modern phenotype of PHPT. A number of observational studies suggest that mild PHPT is associated with depression, decreased quality of life, and changes in cognition, but limited data from randomized controlled trials (RCTs) have not indicated consistent benefits after surgery. The increased cardiovascular morbidity and mortality in severe PHPT has not been definitively demonstrated in mild disease, although there is some evidence for more subtle cardiovascular abnormalities, such as increased vascular stiffness, among others. Results from observational studies that have assessed the effect of PTX on cardiovascular health have been conflicting. The single RCT in this area did not demonstrate that PTX was beneficial. Despite recent progress in these areas, more data from rigorously designed studies are needed to better inform the clinical management of patients with asymptomatic PHPT.
Copyright © 2013 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23374740      PMCID: PMC3564501          DOI: 10.1016/j.jocd.2012.11.008

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  95 in total

1.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

2.  Assessment of left ventricular diastolic function and the Tei index by tissue Doppler imaging in patients with primary hyperparathyroidism.

Authors:  Merih Baykan; Cihangir Erem; Turan Erdogan; Halil Onder Ersöz; Omer Gedikli; Levent Korkmaz; Mehmet Kücükosmanoglu; Arif Haclhasanoglu; Sahin Kaplan; Sükrü Celik
Journal:  Clin Endocrinol (Oxf)       Date:  2007-04       Impact factor: 3.478

3.  Prospective evaluation of quality of life (SF-36v2) and nonspecific symptoms before and after cure of primary hyperparathyroidism (1-year follow-up).

Authors:  Cécile Caillard; Frédéric Sebag; Muriel Mathonnet; Hélène Gibelin; Laurent Brunaud; Coralie Loudot; Jean-Louis Kraimps; Antoine Hamy; Laurent Bresler; Bernard Charbonnel; Joel Leborgne; Jean-François Henry; Jean-Michel Nguyen; Eric Mirallié
Journal:  Surgery       Date:  2007-02       Impact factor: 3.982

4.  Increased risk of cardiac death in primary hyperparathyroidism: what is a role of electrical instability?

Authors:  Mario Curione; Claudio Letizia; Silvia Amato; Simonetta Di Bona; Fabio Di Fazio; Salvatore Minisola; Gianfranco Mazzuoli; Emilio D'Erasmo
Journal:  Int J Cardiol       Date:  2006-11-14       Impact factor: 4.164

5.  Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial.

Authors:  Jens Bollerslev; Svante Jansson; Charlotte L Mollerup; Jörgen Nordenström; Eva Lundgren; Ove Tørring; Jan-Erik Varhaug; Marek Baranowski; Sylvi Aanderud; Celina Franco; Bo Freyschuss; Gunhild A Isaksen; Thor Ueland; Thord Rosen
Journal:  J Clin Endocrinol Metab       Date:  2007-02-06       Impact factor: 5.958

6.  Acute pancreatitis in primary hyperparathyroidism: a population-based study.

Authors:  Teck Kim Khoo; Santhi Swaroop Vege; Haitham S Abu-Lebdeh; Euijung Ryu; Sarah Nadeem; Robert A Wermers
Journal:  J Clin Endocrinol Metab       Date:  2009-03-24       Impact factor: 5.958

7.  Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial.

Authors:  Elena Ambrogini; Filomena Cetani; Luisella Cianferotti; Edda Vignali; Chiara Banti; Giuseppe Viccica; Annalisa Oppo; Paolo Miccoli; Piero Berti; John P Bilezikian; Aldo Pinchera; Claudio Marcocci
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

8.  Coronary artery calcification in patients with primary hyperparathyroidism in comparison with control subjects from the multi-ethnic study of atherosclerosis.

Authors:  Elizabeth A Streeten; Kashif Munir; Scott Hines; Asif Mohamed; Charles Mangano; Kathleen A Ryan; Wendy Post
Journal:  Endocr Pract       Date:  2008-03       Impact factor: 3.443

Review 9.  Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.

Authors:  Shonni J Silverberg; E Michael Lewiecki; Leif Mosekilde; Munro Peacock; Mishaela R Rubin
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

10.  Impairment of flow mediated vasodilatation of brachial artery in patients with primary hyperparathyroidism.

Authors:  Merih Baykan; Cihangir Erem; Turan Erdoğan; Arif Hacihasanoğlu; Omer Gedikli; Abdulkadir Kiriş; Mehmet Küçükosmanoğlu; Halil Onder Ersöz; Sükrü Celik
Journal:  Int J Cardiovasc Imaging       Date:  2006-10-12       Impact factor: 2.316

View more
  8 in total

1.  Italian Society of Endocrinology Consensus Statement: definition, evaluation and management of patients with mild primary hyperparathyroidism.

Authors:  C Marcocci; M L Brandi; A Scillitani; S Corbetta; A Faggiano; L Gianotti; S Migliaccio; S Minisola
Journal:  J Endocrinol Invest       Date:  2015-03-28       Impact factor: 4.256

2.  Ossification of the cervical ligamentum flavum and osseous brown tumor: late manifestations of primary hyperparathyroidism misdiagnosed in a case of parathyroid carcinoma.

Authors:  Nikolaos Sampanis; Eleni Gavriilaki; Eleni Paschou; Asterios Kalaitzoglou; Sotirios Vasileiou
Journal:  Clin Cases Miner Bone Metab       Date:  2016-05-11

3.  Unusual presentation of primary hyperparathyroidism: report of three cases.

Authors:  Ruibin Huang; Ruyao Zhuang; Yuan Liu; Tianti Li; Jiexiong Huang
Journal:  BMC Med Imaging       Date:  2015-07-16       Impact factor: 1.930

Review 4.  Emerging evidence on the link between depressive symptoms and bone loss in postmenopausal women.

Authors:  Elizabeth Mollard; Laura Bilek; Nancy Waltman
Journal:  Int J Womens Health       Date:  2017-12-28

5.  Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism.

Authors:  Patrícia Nunes Mesquita; Ana Paula Dornelas Leão Leite; Stella das Chagas Crisóstomo; Enio Veras Filho; Lucas da Cunha Xavier; Francisco Bandeira
Journal:  Vasc Health Risk Manag       Date:  2017-06-22

6.  Do Symptoms and Serum Calcium Levels Affect the Results of Surgical Treatment of Primary Hyperparathyroidism?

Authors:  QingAn Yu; KunPeng Liu; DaKun Ma; ChangMing Xie; YaoHua Wu; WenJie Dai; HongChi Jiang
Journal:  Biomed Res Int       Date:  2019-07-01       Impact factor: 3.411

Review 7.  Primary Hyperparathyroidism.

Authors:  Leonardo Bandeira; John Bilezikian
Journal:  F1000Res       Date:  2016-01-04

8.  Rare Skeletal Complications in the Setting of Primary Hyperparathyroidism.

Authors:  Nikos Sabanis; Eleni Gavriilaki; Eleni Paschou; Asterios Kalaitzoglou; Dimitrios Papanikolaou; Pinelopi Ioannidou; Sotirios Vasileiou
Journal:  Case Rep Endocrinol       Date:  2015-11-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.